News
Eyenovia to Participate in a Presbyopia Panel Discussion at Eyecelerator 2021
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that Eyenovia will be
Cyanotech Reports Financial Results for the Fourth Quarter and Fiscal Year 2021
Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the fourth
Eyenovia Announces Appointment of Renowned Ophthalmologist and Scientific Leader Dr. Julia Haller to its Board of Directors
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today
Eyenovia and EVERSANA Announce Partnership to Support the Potential Launch and Commercialization of MydCombi™ for Mydriasis
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary Microdose Array Print (MAP™) platform technology, and EVER
Eyenovia Announces Publication of MIST Pivotal Studies Demonstrating the Efficacy and Safety of its MAP™ Fixed-Combination Tropicamide-Phenylephrine Product for Mydriasis
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today
Eyenovia Announces FDA Acceptance of the MydCombi NDA
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the U.S. Food and Drug
Eyenovia to Present at the Ophthalmology Innovation Summit (OIS) Presbyopia Innovation Showcase
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that Dr. David Wirta will
Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis with MydCombi Targeting 80 Million Patient Encounters in the U.S. Annually
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company with Phase 3 programs in presbyopia, myopia and mydriasis, today announced that it has submitted a New Drug
Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopia
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the first set of
Eyenovia Announces FDA Acceptance of IND for MicroLine for Presbyopia, Clearing Path to Initiate Phase 3 VISION Trial by Year End
Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the U. S. Food and
No Brainer Club: Ex-Empfehlung mit +2.409% in 7 Monaten
Cardiff Oncology (WKN: A2P4GU) ist einer der diesjährigen Überflieger an der Nasdaq. Seit ihrem Jahrestief bei 0,70 USD steht für die Aktie eine gigantische Performance von +2.409% in nur sieben
Novus Therapeutics Announces One-for-Eighteen Reverse Stock Split
Novus Therapeutics, Inc. (NASDAQ : NVUS) today announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a reverse stock split of its
Novus Therapeutics to Present at H.C. Wainwright and Cantor Global Investment Conferences
Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biotechnology company targeting the CD40L pathway to develop potential treatments for organ or cell-based transplant, autoimmune
Novus Therapeutics Announces Acquisition of Anelixis Therapeutics
Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS) today announced it has completed the acquisition of Anelixis Therapeutics, Inc. (“Anelixis”), a privately held clinical stage biotechnology company
Heat Biologics: Erste NBC-Empfehlung mit +1.375% in 5 Monaten
Mit Heat Biologics (WKN: A2JB4Y) kannte die erste Empfehlung des weltweit einzigartig erfolgreichen No Brainer Clubs zuletzt kein Halten mehr. Seit Ende Februar steht eine Kursperformance von
Digirad Celebrates the 20th Anniversary of the First Commercially Performed Solid-state Nuclear Medicine Scan
Digirad, a leading provider of nuclear imaging and diagnostic expertise, is celebrating the 20th anniversary of the first commercially performed solid-state nuclear medicine image being scanned
Novus Therapeutics Announces Topline Results of Phase 2a Clinical Trial of OP0201 in Acute Otitis Media
Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today announced topline results
Novus Therapeutics Reports First Quarter 2020 Financial Results
Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today announced financial
Corona-Aktien kaufen: Heat Biologics ist Geschichte!
Anfang des Monats berichteten wir über den ausgebrochenen Corona-Hype rund um Heat Biologics (WKN: A2JB4Y). Die Firma wurde auch in der Folgezeit nicht müde, die Krise für sich zu nutzen.
Satte 5
Novus Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results
Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today announced financial
Heat Biologics mit +210% in 2 Tagen – dank Corona!
Als einer der meistdiskutierten Werte in unserem Live Chat macht die Aktie von Heat Biologics (WKN: A2JB4Y) aktuell mit einem Höhenflug von +210% innerhalb von nur zwei Tagen auf sich aufmerksam
Novus Therapeutics Completes Enrollment of Phase 2a Trial of OP0201 in Pediatric Patients with Acute Otitis Media
Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today announced that it has
Palatin: Aktie fällt – wer greift nach dem Sex-Pen?
Im vergangenen Jahr feierten SD-Leser bis zu +600% Kursgewinn mit der Aktie von Palatin Technologies (WKN: A1C538). Wir rieten rechtzeitig zum Ausstieg, bevor der Kurs wieder stark nachgab. Doch
Cidara: NBC kassiert +136% plus Bonus!
Der No Brainer Club empfahl die Aktie von Cidara Therapeutics (WKN: A14R2R) am 26. September letzten Jahres „stark zu kaufen“. Seitdem steht ein zwischenzeitlicher Kursgewinn von +134% zu Buche
Novus Therapeutics Provides Update on OP0201
Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today provided an update on the